Randomized trial of three phototherapy methods for the treatment of acne vulgaris in <scp>C</scp>hinese patients

Fan, Xin; An, Yu-Xi; Zhou, Jin; Wang, Congmin

doi:10.1111/phpp.12098

Cited by 40 publications

(35 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, a high proportion of patients with severe acne (baseline IGA 4) benefited from this treatment. Study treatment was safe and very well tolerated, as previously reported, for blue light therapy …”

Section: Discussionsupporting

confidence: 73%

A multicenter, randomized, split‐face clinical trial evaluating the efficacy and safety of chromophore gel‐assisted blue light phototherapy for the treatment of acne

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 73%

A multicenter, randomized, split‐face clinical trial evaluating the efficacy and safety of chromophore gel‐assisted blue light phototherapy for the treatment of acne

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Compliance was excellent despite the young age of the patients and the long study period (at least 24 weeks considering the total duration of the Main and the Extension trials). Serious adverse events after treatment were not observed and as previously reported the BioPhotonic System was safe and well tolerated . One limitation of this trial might be that most the patients included were female (71%).…”

Section: Discussionmentioning

confidence: 77%

An extension of a multicenter, randomized, split‐face clinical trial evaluating the efficacy and safety of chromophore gel‐assisted blue light phototherapy for the treatment of acne

et al. 2017

View full text Add to dashboard Cite

A variety of laser/light-based devices have been reported to be effective for the treatment of acne, yet no long-term data on efficacy and safety have been published. A first 12-week clinical trial ("Main trial") recently demonstrated that the KLOX BioPhotonic System, an LED blue light device using photo-converter chromophores, can significantly improve moderate and severe facial acne vulgaris with an excellent safety profile. This Extension trial followed the Main trial, using the same BioPhotonic System, with the same dose and instructions for use, on patients having already completed treatment in the Main trial. Main objectives of this open-label long-term extension 12-week study were to evaluate the efficacy of the KLOX BioPhotonic System on the untreated hemiface during the Main trial, as well as the duration of response on the hemiface treated during the first 12-week Main trial. Despite their young age (mean age: 21.6 years) and their 12-week participation in the Main trial, 49 (54.4%) of the total number of patients who participated in the Main trial enrolled in this additional 12-week Extension trial. Baseline grading of acne was performed with the Investigator's Global Assessment (IGA) scale. For each patient, the hemiface randomly selected as a control during the Main trial received 6 weeks of treatment (twice weekly) and was then followed up for an additional 6 weeks. The first hemiface treated in the Main trial was consequently observed throughout the Extension trial, allowing for a further 12-week assessment of outcomes (total 24 weeks). In light of an additional 12 weeks of treatment on the contralateral face, the patient compliance rate was excellent, with 91.9% of the total number of patients receiving at least 80% of the treatments.Patients with a baseline IGA grade of 2 (mild) on the treated hemiface demonstrated a success rate of 58.3 and 66.7% at weeks 6 and 12, respectively. At these same time points, subjects with a baseline IGA grade of 3 (moderate) demonstrated a success rate of 81.8 and 90.0%. Patients with a baseline IGA grade of 4 (severe) demonstrated a success rate of 100% at both week 6 and week 12. When evaluating the originally treated hemifaces from the Main trial, the rate of return to baseline at 24 weeks was calculated to be 15.5%. This latter outcome confirmed the long duration of effect following treatment.The patient safety profile was also excellent, with very few related adverse events. The BioPhotonic System, which is comprised of LED blue light phototherapy and photoconverter chromophores, provides long-term efficacy and safety in the treatment of acne vulgaris, with a rate of compliance above what is generally observed in a young population of patients suffering from acne vulgaris, especially in light of sequential enrollment in a study treating one hemiface.

show abstract

“…LPDL, which uses a wavelength of 595 nm, was more effective at decreasing ILC in patients with mild to severe acne when combined with PDT (67% vs. 100%) [70, 71]. Treatment with red (620–660 nm) and blue (400–500 nm) light are both moderately effective at decreasing ILC (up to 66% and up to 77%, respectively), and these efficacies can be enhanced when combined with PDT [58, 64, 67, 72–82]. Red light PDT appears to be more effective when the photosensitizer is incubated under occlusion compared to no occlusion (59.4% and 31.7% ILC reduction, respectively) [80].…”

Section: Resultsmentioning

confidence: 99%

“…Red light PDT appears to be more effective when the photosensitizer is incubated under occlusion compared to no occlusion (59.4% and 31.7% ILC reduction, respectively) [80]. Blue-red (400–500 plus 620–660 nm) light therapy may be superior to either blue or red light alone, with ILC reductions of up to 90% reported [58, 83–85]. …”

Section: Resultsmentioning

confidence: 99%

Optimizing Non-Antibiotic Treatments for Patients with Acne: A Review

Canavan

Chen

Elewski

2016

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Acne is a very common non-infectious skin condition that is frequently treated in dermatological practices. Because acne is often chronic and may persist for years, safe and effective long-term maintenance therapy is often required. Given the increasing frequency of antibiotic-resistant bacteria and the gravity of the consequences of this trend, it behooves dermatologists to maximize use of non-antimicrobial therapy when treating acne. In this review of the literature we present data regarding the efficacy and appropriate use of non-antimicrobial treatments for acne. A variety of topical and oral treatment options exist that can be used in a step-wise manner according to the patients’ severity and therapeutic response. Non-antimicrobial treatments can be highly efficacious at controlling acne, especially when used as maintenance therapy. While antibiotics have a role in acne treatment, they should not be used as monotherapy, and lengthy courses of antibiotic use are discouraged.

show abstract

Randomized trial of three phototherapy methods for the treatment of acne vulgaris in Chinese patients

Abstract: Phototherapy is efficacious for moderate to severe facial acne vulgaris.

Cited by 40 publications

References 39 publications

A multicenter, randomized, split‐face clinical trial evaluating the efficacy and safety of chromophore gel‐assisted blue light phototherapy for the treatment of acne

A multicenter, randomized, split‐face clinical trial evaluating the efficacy and safety of chromophore gel‐assisted blue light phototherapy for the treatment of acne

An extension of a multicenter, randomized, split‐face clinical trial evaluating the efficacy and safety of chromophore gel‐assisted blue light phototherapy for the treatment of acne

Optimizing Non-Antibiotic Treatments for Patients with Acne: A Review

Contact Info

Product

Resources

About